CUE Cue Biopharma
Company Analysis
Latest News
🔴 Cue Biopharma is trading 13.65% down today after Q2 net loss rose to $153.1 million
Cue Biopharma is trading at $29.53, down -13.65% after August 14, 2026, Q2 earnings showed a $153.1 million net loss, versus $8.5 million a year earlier. -...
🔴 Cue Biopharma is trading 6.1% down today after second-quarter net loss widened to $153.1 million
Cue Biopharma is trading 6.1% down at $32.12 after investors reassessed its August 14 second-quarter results. - Revenue rose to $7.9 million from $3.0...
Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 18, 2026
Analyst consensus points to Q2 revenue of $3.00 million and an EPS loss of -$1.69, while the stock currently trades at $34.20, significantly below the average...
Cue Biopharma Downgraded to Hold, Following $1.6 Million CEO Stock Sale
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from buy to hold on Saturday. The action follows the company’s August 14 second-quarter earnings report....
Cue Biopharma second quarter 2026 revenue hits $7.9M as CUE-221 acquisition expenses drive losses
Cue Biopharma reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million year-over-year, driven by milestones from its Boehringer...
🔴 Cue Biopharma is trading 6.73% down in after-hours trading as immediate catalyst remains unclear
Cue Biopharma is trading 6.73% down at $31.90 after closing at $34.20 on August 14, 2026; the immediate catalyst remains unclear. - No confirmed...
🟢 Cue Biopharma is trading 11.33% up today with no confirmed catalyst
Cue Biopharma is trading 11.33% up at $34.60, with the cause unclear. - Gains extended from August 11 through August 13; no verified company-specific...
🟢 Cue Biopharma is trading 5.86% up today with no verified company-specific catalyst
Cue Biopharma is trading 5.86% up at $32.90, with no verified company-specific announcement dated August 14, 2026 identified. - The latest official company...
🟢 Cue Biopharma is trading 6% up today as flat July PPI eased rate-hike concerns
Cue Biopharma is trading 5.95% up at $32.23, likely supported by broader risk-on sentiment after flat July PPI eased rate-hike concerns. - No verified...
🔴 Cue Biopharma is trading 10.47% down today with no clear catalyst
Cue Biopharma is trading at $27.23 (-10.47%) after no verified company-specific announcement was identified for August 13, 2026. • The latest official...
🔴 Cue Biopharma is trading 6.25% down today with no verified company-specific announcement identified
Cue Biopharma is trading 6.25% down at $28.52 after no verified company-specific announcement was identified for August 13, 2026. - The latest official...
🟢 Cue Biopharma is trading 5.84% up today with catalyst unconfirmed
Cue Biopharma is trading at $29.89 (+5.84%), with the catalyst unconfirmed. - No verified company-specific announcement is dated August 12, 2026. - The latest...
🔴 Cue Biopharma is trading 5.77% down today with no verified company-specific catalyst identified
Cue Biopharma is trading 5.77% down at $26.61 after no verified company-specific catalyst was identified for August 12, 2026. - Latest official company news...
🟢 Cue Biopharma is trading 5.17% up in pre-market; no verified company-specific catalyst identified
Cue Biopharma is trading 5.17% up in pre-market at $29.70, with no new verified company-specific announcement identified to explain the move. - It rose 8.20%...
🟢 Cue Biopharma is trading 5.6% up in after-hours trading; catalyst remains unconfirmed
Cue Biopharma is trading at $29.82, up +5.61%, while the catalyst remains unconfirmed. - Gained 8.20% during the August 11 regular session before extending...
🟢 Cue Biopharma is trading 12.34% up today — catalyst unconfirmed
Cue Biopharma is trading 12.34% up at $29.32 after no clear company-specific announcement was identified for August 11, 2026. - Investor-relations page lists...
🔴 Cue Biopharma is trading 5.59% down today; immediate catalyst unclear
Cue Biopharma is trading 5.59% down at $25.61, reversing pre-market strength ahead of the expected August 11 earnings report; the immediate catalyst remains...
🟢 Cue Biopharma is trading 5% up in pre-market ahead of expected August 11 earnings report
Cue Biopharma is trading at $28.48, up +5.01% in pre-market, with investors potentially positioning ahead of the expected August 11 earnings report, where...
Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Cue Biopharma to report a consensus loss of $1.38 per share on revenue of $3.0 million, with the current stock...
🟢 Cue Biopharma rises 5.1% — Biotech Sector Rallies on Argenx-Forte M&A Deal
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher, with the XBI ETF...